Status:
UNKNOWN
Treatment of Chronic Active Antibody Mediated Rejection After Kidney Transplantation by Double-Filtration PlasmaPheresis or Plasma Exchange
Lead Sponsor:
University Hospital, Grenoble
Conditions:
Kidney Transplantation
Antibody Mediated Rejection
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
In France around 90,000 cases of end-stage chronic kidney disease patients treated either by dialysis (60%) or renal transplantation (just over 40%). In terms of patient survival and quality of life ...
Detailed Description
Each year in the Renal Nephrology and Transplantation Department of Grenoble Hospital treat about twenty renal transplant patients with chronic active antibody rejection. Some patients are diagnosed a...
Eligibility Criteria
Inclusion
- To be enrolled into the study, subjects must meet all of the following inclusion criteria
- Kidney transplantation for more than 6 months
- The presence of one or more DSAs with MFI greater than 1000
- Renal Graft dysfunction with renal biopsy of humoral rejection or chronic active antibody mediated rejection lesions based on the 2017 banff score ( with/without C4d)
- Written informed consent in patients
Exclusion
- Subjects must not be enrolled into the study if they meet any of the following exclusion criteria:
- Kidney transplant for less than 6 months.
- MFI\<1000
- Hemoglobin level\<110 g/l
- No vascular access patients
- Pre terminal histological lesions of chronic ABMR
- Subject in exclusion period of another study
- Pregnant women, parturient or breastfeeding
- Subject under administrative or judicial control
Key Trial Info
Start Date :
July 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2021
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT03436134
Start Date
July 1 2018
End Date
March 1 2021
Last Update
March 27 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Grenoble Alpes University Hospital
La Tronche, France, 38700